Search alternatives:
point decrease » point increase (Expand Search)
et decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i et » i e (Expand Search), i ex (Expand Search)
point decrease » point increase (Expand Search)
et decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i et » i e (Expand Search), i ex (Expand Search)
-
40201
The effect of acetylcysteine on the prothrombin time and international normalized ratio: a narrative review
Published 2025“…This increase was dose-dependent and was caused by a decrease in the activity of coagulation factors II, VII, IX and X. …”
-
40202
Bicarbonate concentration and pH value in the PF in a canine AP model.
Published 2016“…<p>AP was induced by a retrograde injection of 5% sodium taurocholate (0.5 ml/kg) via the main pancreatic duct. …”
-
40203
Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes
Published 2017“…The dosage form for Mef is mostly available as adult tablets, and thus children under the age of 5 suffer from poor medication adherence. We have developed a stable, rapidly dissolvable, and palatable pediatric formulation for Mef using liposomes composed of 1,2-distearoyl-<i>sn</i>-glycero-3-phosphocholine (DSPC) and cholesterol with a mean diameter of ∼110 nm. …”
-
40204
Table_1_Triglyceride affects the association between estimated glomerular filtration rate and the onset of non-alcoholic fatty liver disease: A second analysis of a Chinese cohort...
Published 2022“…Further, compared to non-HTG subjects with eGFR ≥ 116.56 ml/min/1.73 m<sup>2</sup>, participants with HTG and eGFR < 82.88 ml/min/1.73 m<sup>2</sup> had about a fourfold increase in the risk (HR = 4.852 95% CI: 3.943–5.970) of NAFLD.…”
-
40205
-
40206
Use of quantitative proteomics identifies a putative TvROM1 substrate.
Published 2015“…<b>(C)</b> The predicted TM domains of the five putative substrates identified in <b>A</b>, and the percent decrease in protein levels with 3,4-DCI <i>vs</i>. …”
-
40207
Lymphatic density (LD; a) and blood vessel density (BD; b) in the myocardium
Published 2011“…The values of BD are 2693.4 ± 197.0 in Normal, 1689.9 ± 640.7 in Stage I, 571.4 ± 478.3 in Stage II, 51.8 ± 30.5 in Stage III, 1430.8 ± 323.1 in Stage IV, 1292.7 ± 153.1 in Stage V, 509.9 ± 276.3 in Stage VI and 130.5 ± 83.8 in Stage VII. …”
-
40208
Interpretation on the model parameters.
Published 2025“…<div><p>Cholera is a bacterial water-borne diarrheal disease transmitted via the fecal-oral route that causes high morbidity in sub-Saharan Africa and Asia. …”
-
40209
-
40210
-
40211
DataSheet1_Investigations of potential non-amino acid SNAT2 inhibitors.docx
Published 2024“…In contrast to the previous publication, MMTC showed no inhibition of SNAT2-mediated <sup>3</sup>H-Gly uptake in PC-3 cells at a concentration of 1 or 5 μM, despite a published IC<sub>50</sub> of 0.8 µM. …”
-
40212
DataSheet1_Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach.pdf
Published 2021“…AUC and C<sub>max</sub> GMR (95%CI) of atorvastatin, another CYP3A substrate, was increased 2.14 (1.52–3.02) fold in healthy elderly and 4.15 (2.98–5.79) fold in elderly patients with CKD, indicating decreased CYP3A activity related to ageing. …”
-
40213
Data_Sheet_1_Empty Sella Syndrome as a Window Into the Neuroprotective Effects of Prolactin.pdf
Published 2021“…Hormone testing was conducted in tandem with routine clinical evaluations over 1 year and the patient was followed with diffusion magnetic resonance imaging (dMRI), optical coherence tomography (OCT), and automated perimetry at three time points. Five healthy controls underwent a complementary battery of clinical and neuroimaging tests at a single time point.…”
-
40214
-
40215
Efficient Lewis Acid Promoted Alkene Hydrogenations Using Dinitrosyl Rhenium(−I) Hydride Catalysts
Published 2013“…Highly efficient alkene hydrogenations were developed using NO-functionalized hydrido dinitrosyl rhenium catalysts of the type [ReH(PR<sub>3</sub>)<sub>2</sub>(NO)(NO(LA))][Z] (<b>2</b>, LA = B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>; <b>3</b>, LA = [Et]<sup>+</sup>, Z = [B(C<sub>6</sub>F<sub>5</sub>)<sub>4</sub>]<sup>−</sup>; <b>4</b>, LA = [SiEt<sub>3</sub>]<sup>+</sup>, Z = [HB(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>]<sup>−</sup>; R = <i>i</i>Pr <b>a</b>, Cy <b>b</b>). …”
-
40216
Efficient Lewis Acid Promoted Alkene Hydrogenations Using Dinitrosyl Rhenium(−I) Hydride Catalysts
Published 2013“…Highly efficient alkene hydrogenations were developed using NO-functionalized hydrido dinitrosyl rhenium catalysts of the type [ReH(PR<sub>3</sub>)<sub>2</sub>(NO)(NO(LA))][Z] (<b>2</b>, LA = B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>; <b>3</b>, LA = [Et]<sup>+</sup>, Z = [B(C<sub>6</sub>F<sub>5</sub>)<sub>4</sub>]<sup>−</sup>; <b>4</b>, LA = [SiEt<sub>3</sub>]<sup>+</sup>, Z = [HB(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>]<sup>−</sup>; R = <i>i</i>Pr <b>a</b>, Cy <b>b</b>). …”
-
40217
Efficient Lewis Acid Promoted Alkene Hydrogenations Using Dinitrosyl Rhenium(−I) Hydride Catalysts
Published 2013“…Highly efficient alkene hydrogenations were developed using NO-functionalized hydrido dinitrosyl rhenium catalysts of the type [ReH(PR<sub>3</sub>)<sub>2</sub>(NO)(NO(LA))][Z] (<b>2</b>, LA = B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>; <b>3</b>, LA = [Et]<sup>+</sup>, Z = [B(C<sub>6</sub>F<sub>5</sub>)<sub>4</sub>]<sup>−</sup>; <b>4</b>, LA = [SiEt<sub>3</sub>]<sup>+</sup>, Z = [HB(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>]<sup>−</sup>; R = <i>i</i>Pr <b>a</b>, Cy <b>b</b>). …”
-
40218
Efficient Lewis Acid Promoted Alkene Hydrogenations Using Dinitrosyl Rhenium(−I) Hydride Catalysts
Published 2013“…Highly efficient alkene hydrogenations were developed using NO-functionalized hydrido dinitrosyl rhenium catalysts of the type [ReH(PR<sub>3</sub>)<sub>2</sub>(NO)(NO(LA))][Z] (<b>2</b>, LA = B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>; <b>3</b>, LA = [Et]<sup>+</sup>, Z = [B(C<sub>6</sub>F<sub>5</sub>)<sub>4</sub>]<sup>−</sup>; <b>4</b>, LA = [SiEt<sub>3</sub>]<sup>+</sup>, Z = [HB(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>]<sup>−</sup>; R = <i>i</i>Pr <b>a</b>, Cy <b>b</b>). …”
-
40219
Efficient Lewis Acid Promoted Alkene Hydrogenations Using Dinitrosyl Rhenium(−I) Hydride Catalysts
Published 2013“…Highly efficient alkene hydrogenations were developed using NO-functionalized hydrido dinitrosyl rhenium catalysts of the type [ReH(PR<sub>3</sub>)<sub>2</sub>(NO)(NO(LA))][Z] (<b>2</b>, LA = B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>; <b>3</b>, LA = [Et]<sup>+</sup>, Z = [B(C<sub>6</sub>F<sub>5</sub>)<sub>4</sub>]<sup>−</sup>; <b>4</b>, LA = [SiEt<sub>3</sub>]<sup>+</sup>, Z = [HB(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>]<sup>−</sup>; R = <i>i</i>Pr <b>a</b>, Cy <b>b</b>). …”
-
40220